Field Medical, a clinical-stage company developing pulsed field ablation technology for cardiac arrhythmias, closed a $35 million Series B financing round co-led by BioStar Capital and Cue Growth, with participation from existing strategic investors. The funds will support the initiation of the pivotal VERITAS trial and further development of the FieldForce Ablation System.
Related articles
Press ReleaseMay 8, 2026
West Enclave Merger Corp. Announces the Separate Trading of its Ordinary Shares and Rights, Commencing May 13, 2026
May 8, 2026
Press ReleaseMay 8, 2026
Shreya Acquisition Group Announces Closing of $110 Million Initial Public Offering (Including Partial Exercise of Over-Allotment Option)
May 8, 2026
Press ReleaseMay 8, 2026
Con Edison Announces $2 Billion At-The-Market (ATM) Equity Offering Program
May 8, 2026
← Back to all articles
Generated by Yeal